Publications

5491 Results

Correlations Between First Cycle Toxicity and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)

Authors
M Othus;S Patel;YK Chae;E Dietrich;H Streicher;E Sharon;R Kurzrock
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 2655)
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Correlation of Body Mass Index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of Patient (pt) Level Data from SWOG 1216 study

Authors
U Swami;Y Jo;A Narang;M Plets;C Chehade;G Gebrael;S Gupta;Z Myint;C Tangen;P Lara;I Thompson;M Hussain;T Dorff;S Lerner;N Agarwal
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 5081)
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1216

SWOG S2302, PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab plus Pembrolizumab (PR) versus Standard of Care (SOC) for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Authors
K Reckamp;M Redman;K Dragnev;W Iams;B Henick;J Miao;D Carrizosa;RS Herbst;J Gray
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS8657)
Year
2024
Research Committee(s)
Lung
Study Number(s)
S2302

SWOG S2012: Randomized Phase II/III Trial of First Line Platinum (P) / Etoposide (E) with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Authors
D Zhen;A Moseley;EG Chiorean;E Burgess;E Swisher;C Gay;L Byers;I Wistuba;H Mahdi;J Starr;M Othus;Y Chae;R Kurzrock
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS4201)
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S2012

A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937- Updated Design

Authors
S Sadeghi;M Plets;P Lara;C Tangen;S Berg;J Brown;R Bangs;D Nakagawa;S Daneshmand;I Thompson;T Flaig;D Petrylak;S Lerner
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS4617)
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1937

Association between Postoperative Circulating Tumor DNA (ctDNA) and Recurrence-Free Survival (RFS) in Patients with Resected Stage III Melanoma - an Exploratory Analysis of SWOG S1404

Authors
M LaPelusa;D Marcano;M Othus;A Grossmann;V Aushev;B Sridhar;D Renner;H Sethi;M Liu;A Tarhini;J Kirkwood;K Grossmann;J Moon;H Li;S Mashrun;N Khushalani;E Sharon;L Korde;A Ribas;S Patel
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 9564)
Year
2024
Research Committee(s)
Melanoma
Study Number(s)
S1404

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia (AML) treated on SWOG S1203

Authors
S Raychaudhuri;M Othus;M Percival;G Garcia-Manero;F Appelbaum;H Erba;J Appelbaum
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 6529)
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
S1203

Lung-MAP S1800D: A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy

Authors
J Wrangle;M Redman;H Husain;K Reckamp;T Stinchcombe;M Edelman;T Leal;B Faller;K Minichiello;H Borghaei;RS Herbst;JE Gray
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 2619)
Year
2024
Research Committee(s)
Lung
Study Number(s)
S1800D

Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Patients with Early-Stage Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481)

Authors
M Trivedi;J Unger;D Hershman;A Darke;D Hertz;T Brannagan;S Smith;B Schneider;W Irvin;A Hathaway;A Vander Woude;V Gudena;P Cabrera-Galean;M Orsted;M LeBlanc;NL Henry;MJ Fisch
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral; J Clin Oncol 42, 2024 (suppl 16; abstr 12005)
Year
2024
Research Committee(s)
Symptom Control and Quality of Life
Study Number(s)
S1714

Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)

Authors
K Kalinsky;W Barlow;H Pathak;J Gralow;K Albain;D Hayes;N Lin;E Perez;L Goldstein;S Chia;P Rastogi;A Schott;S Shak;D Tripathy;G Hortobagyi;F Meric-Bernstam;P Sharma;L Pusztai;A Thompson;A Godwin
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral presentation; J Clin Oncol 42, 2024 (suppl 16; abstr 505)
Year
2024
Research Committee(s)
Breast
Study Number(s)
S1007